Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer

NCT00129844 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT00129844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2007
Enrollment
108 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, lung neoplasms, non-small-cell lung carcinoma